How and where to order Cytotec (Misoprostol) 100 mcg, 200 mcg tablets or capsules online:
|Shop:||CHEAP MEDS FOR SALE
|Prices:||from $1.35 per pill
|Discount:||5% coupon: 5OFF
|Forms:||100 mcg, 200 mcg tablets
|Type:||Misoprostol brand, Cytotec generic
|Payment:||Visa, MasterCard, AmEx, Bitcoin
|Delivery:||Regular and express mail service
|Shipping:||Worldwide, including USA, UK, Europe, Canada, Australia
Misoprostol (trade names include Cytotec, Apo-Misoprostol, Cytolog, Misoprost, Gymiso, Misotrol) is a medication from prostaglandin E1 (PGE1) analogues pharmacological group. This medicine is used to prevent development of stomach ulcers, which may sometimes be caused by arthritis medications that are called non-steroidal anti-inflammatory drugs (NSAIDs). Misoprostol works by reducing the amount of acid released by the stomach and protecting the stomach lining, which helps to reduce the risk of stomach ulcers. Cytotec (Misoprostol) is indicated to treat acute ulcers in the stomach (gastric ulcers), or in the first part of the small intestine (duodenal ulcers) and to prevent bleeding in the stomach or upper intestine in hospital patients after surgery.
Misoprostol is also indicated for medical abortions as an alternative to surgical abortion. Medical abortion (induction of labour) has the advantage of being cheaper, simpler, less invasive, not requiring anesthesia, and not having the risk of scarring and adhesions associated with surgical abortion. Thats why Misoprostol is also called as "abortion pills".
Carboprost (Hemabate, Prostodin)
Dinoprost (Enzaprost-F, Prostin-F2 Alpha)
Dinoprostone (Propess, Prostin-E2)
Gemeprost (Cervagem, Cervidil)
Pharmacological and medical categories:
Antacids, antireflux agents and antiulcerants
Drugs acting on the uterus
Medications for medical abortion
Preparations for the treatment of peptic ulcer
Prostaglandins and their analogs
Start labor drugs
A - Alimentary tract and metabolism
A02 - Drugs for acid related disorders
A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)
A02BB - Prostaglandins
A02BB01 - Misoprostol
G - Genito urinary system and sex hormones
G02 - Other gynecologicals
G02A - Uterotonics
G02AD - Prostaglandins
G02AD06 - Misoprostol
Gastric ulcer - K25
Duodenal ulcer - K26
Peptic ulcer, site unspecified - K27
Other diseases of stomach and duodenum - K31
Medical abortion - O04
Other abortion - O05
Unspecified abortion - O06
Failed attempted abortion - O07
Indications and usage:
Cytotec (Misoprostol) is indicated for reducing the risk of NSAID (nonsteroidal anti-inflammatory drugs, including aspirin)–induced gastric ulcers in patients at high risk of complications from gastric ulcer, e.g., the elderly and patients with concomitant debilitating disease, as well as patients at high risk of developing gastric ulceration, such as patients with a history of ulcer. Cytotec has not been shown to reduce the risk of duodenal ulcers in patients taking NSAIDs. Cytotec should be taken for the duration of NSAID therapy. Cytotec has been shown to reduce the risk of gastric ulcers in controlled studies of 3 months' duration. It had no effect, compared to placebo, on gastrointestinal pain or discomfort associated with NSAID use.
Cytotec should not be taken by pregnant women to reduce the risk of ulcers induced by nonsteroidal anti-inflammatory drugs (NSAIDs).
Misoprostol should not be taken by anyone with a history of allergy to prostaglandins.
Dosage and administration:
The recommended adult oral dose of Cytotec (Misoprostol) for reducing the risk of NSAID-induced gastric ulcers is 200 mcg four times daily with food. If this dose cannot be tolerated, a dose of 100 mcg can be used. This medication should be taken for the duration of NSAID therapy as prescribed by the physician. Misoprostol should be taken with a meal, and the last dose of the day should be at bedtime.
Adjustment of the dosing schedule in renally impaired patients is not routinely needed, but dosage can be reduced if the 200-mcg dose is not tolerated.
The toxic dose of Cytotec in humans has not been determined. Cumulative total daily doses of 1600 mcg have been tolerated, with only symptoms of gastrointestinal discomfort being reported. In animals, the acute toxic effects are diarrhea, gastrointestinal lesions, focal cardiac necrosis, hepatic necrosis, renal tubular necrosis, testicular atrophy, respiratory difficulties, and depression of the central nervous system. Clinical signs that may indicate an overdose are sedation, tremor, convulsions, dyspnea, abdominal pain, diarrhea, fever, palpitations, hypotension, or bradycardia. Symptoms should be treated with supportive therapy.
It is not known if Misoprostol acid is dialyzable. However, because this medicine is metabolized like a fatty acid, it is unlikely that dialysis would be appropriate treatment for overdosage.
Cytotec (Misoprostol) administration to women who are pregnant can cause birth defects, abortion, premature birth or uterine rupture.
Uterine rupture has been reported when cytotec was administered in pregnant women to induce labor or to induce abortion. The risk of uterine rupture increases with advancing gestational ages and with prior uterine surgery, including cesarean delivery (see also precautions and labor and delivery).
Cytotec should not be taken by pregnant women to reduce the risk of ulcers induced by nonsteroidal anti-inflammatory drugs (nsaids) (see contraindications, warnings, and precautions).
Patients must be advised of the abortifacient property and warned not to give the drug to others.
Misoprostol tablets should not be used for reducing the risk of NSAID-induced ulcers in women of childbearing potential unless the patient is at high risk of complications from gastric ulcers associated with use of the NSAID, or is at high risk of developing gastric ulceration. In such patients, Cytotec may be prescribed if the patient:
has had a negative serum pregnancy test within 2 weeks prior to beginning therapy.
is capable of complying with effective contraceptive measures.
has received both oral and written warnings of the hazards of misoprostol, the risk of possible contraception failure, and the danger to other women of childbearing potential should the drug be taken by mistake.
will begin Misoprostol only on the second or third day of the next normal menstrual period.
Caution should be employed when administering Cytotec to patients with pre-existing cardiovascular disease.
Special note for women: Misoprostol may cause birth defects, abortion (sometimes incomplete), premature labor or rupture of the uterus if given to pregnant women.
This drug is available only as a unit-of-use package that includes a leaflet containing patient information.
Cytotec (Misoprostol) has not been shown to interfere with the beneficial effects of aspirin on signs and symptoms of rheumatoid arthritis. This medicine does not exert clinically significant effects on the absorption, blood levels, and antiplatelet effects of therapeutic doses of aspirin. Cytotec has no clinically significant effect on the kinetics of diclofenac or ibuprofen.
Prostaglandins such as Misoprostol may augment the activity of oxytocic agents, especially when given less than 4 hours prior to initiating oxytocin treatment. Concomitant use is not recommended.
Information for patients:
Cytotec (Misoprostol) pills are being prescribed by your doctor to decrease the chance of getting stomach ulcers related to the arthritis/pain medication that you take.
Do not take Cytotec to reduce the risk of NSAID-induced ulcers if you are pregnant. Misoprostol can cause abortion (sometimes incomplete which could lead to dangerous bleeding and require hospitalization and surgery), premature birth, or birth defects. It is also important to avoid pregnancy while taking this medication and for at least one month or through one menstrual cycle after you stop taking it. This medication may cause the uterus to tear (uterine rupture) during pregnancy. The risk of uterine rupture increases as your pregnancy advances and if you have had surgery on the uterus, such as a Cesarean delivery. Rupture (tearing) of the uterus can result in severe bleeding, hysterectomy, and/or maternal or fetal death.
If you become pregnant during Cytotec therapy, stop taking this medicine and contact your physician immediately. Remember that even if you are on a means of birth control it is still possible to become pregnant. Should this occur, stop taking Misoprostol and contact your physician immediately.
Cytotec may cause diarrhea, abdominal cramping, and/or nausea in some people. In most cases these problems develop during the first few weeks of therapy and stop after about a week. You can minimize possible diarrhea by making sure you take this drug with food.
Because these side effects are usually mild to moderate and usually go away in a matter of days, most patients can continue to take Misoprostol. If you have prolonged difficulty (more than 8 days), or if you have severe diarrhea, cramping and/or nausea, call your doctor.
Take Cytotec only according to the directions given by your physician.
Do not give this medication to anyone else. It has been prescribed for your specific condition, may not be the correct treatment for another person, and would be dangerous if the other person were pregnant.
This information sheet does not cover all possible side effects of Misoprostol (Cytotec) tablets. This patient information leaflet does not address the side effects of your arthritis/pain medication. See your doctor if you have questions.
Keep out of reach of children.
Adverse reactions, side effects:
The following have been reported as adverse events in subjects receiving Misoprostol (Cytotec) tablets:
In subjects receiving Cytotec 400 or 800 mcg daily in clinical trials, the most frequent gastrointestinal adverse events were diarrhea and abdominal pain. The incidence of diarrhea at 800 mcg in controlled trials in patients on NSAIDs ranged from 14–40% and in all studies (over 5,000 patients) averaged 13%. Abdominal pain occurred in 13–20% of patients in NSAID trials and about 7% in all studies, but there was no consistent difference from placebo.
Diarrhea was dose related and usually developed early in the course of therapy (after 13 days), usually was self-limiting (often resolving after 8 days), but sometimes required discontinuation of Misoprostol (2% of the patients). Rare instances of profound diarrhea leading to severe dehydration have been reported. Patients with an underlying condition such as inflammatory bowel disease, or those in whom dehydration, were it to occur, would be dangerous, should be monitored carefully if Cytotec is prescribed. The incidence of diarrhea can be minimized by administering after meals and at bedtime, and by avoiding coadministration of Cytotec with magnesium-containing antacids.
Women who received this medication during clinical trials reported the following gynecological disorders: spotting (0.7%), cramps (0.6%), hypermenorrhea (0.5%), menstrual disorder (0.3%) and dysmenorrhea (0.1%). Postmenopausal vaginal bleeding may be related to Cytotec administration. If it occurs, diagnostic workup should be undertaken to rule out gynecological pathology.
There were no significant differences in the safety profile of Misoprostol in approximately 500 ulcer patients who were 65 years of age or older compared with younger patients.
Additional adverse events which were reported are categorized as follows (incidence greater than 1%):
In clinical trials, the following adverse reactions were reported by more than 1% of the subjects receiving Cytotec tablets and may be causally related to the drug: nausea (3.2%), flatulence (2.9%), headache (2.4%), dyspepsia (2.0%), vomiting (1.3%), and constipation (1.1%). However, there were no significant differences between the incidences of these events for Misoprostol and placebo.
Use in specific populations:
Teratogenic effects: congenital anomalies sometimes associated with fetal death have been reported subsequent to the unsuccessful use of misoprostol as an abortifacient, but the drug's teratogenic mechanism has not been demonstrated. Several reports in the literature associate the use of misoprostol during the first trimester of pregnancy with skull defects, cranial nerve palsies, facial malformations, and limb defects.
Cytotec (Misoprostol) is not fetotoxic or teratogenic in rats and rabbits at doses 625 and 63 times the human dose, respectively.
Nonteratogenic effects: this drug may endanger pregnancy (may cause abortion) and thereby cause harm to the fetus when administered to a pregnant woman. Cytotec may produce uterine contractions, uterine bleeding, and expulsion of the products of conception. Abortions caused by Misoprostol may be incomplete. If a woman is or becomes pregnant while taking this drug to reduce the risk of NSAID-induced ulcers, the drug should be discontinued and the patient apprised of the potential hazard to the fetus.
Misoprostol is rapidly metabolized in the mother to misoprostol acid, which is biologically active and is excreted in breast milk. There are no published reports of adverse effects of misoprostol in breast-feeding infants of mothers taking misoprostol. Caution should be exercised when misoprostol is administered to a nursing woman.
Safety and effectiveness of Cytotec in pediatric patients have not been established.
X - Australia
X - United States (Should not be used during pregnancy)
Salts and other forms:
Synonyms, international and chemical names:
Brands, generics, trade names:
Alsoben - Unimed Pharmaceuticals, Hien Vi Pharmaceutical
Apo-Misoprostol - Apotex
Cyprostol - Pfizer
Cytolog - Zydus Cadila
Cytotec - Pfizer, GD Searle, Perrigo
Gastrul - Fahrenheit
GyMiso - HRA Pharma
Kontrac - Fourrts India Laboratories
Misodex - Sefarma
Misoprost - Cipla
Misoprostol - IVAX, Pro Doc, Stada
Misotrol - Sanofi-Aventis
Mizoprostol - Beijing Zizhu Pharmaceutical
Noprostol - Novell Pharmaceutical Laboratories
Prestakind - Mankind Pharma
Zitotec - Sun Pharmaceutical Industries
APIs used in medicine in combinations with misoprostol:
Here is a list of popular medications containing misoprostol as a main active pharmaceutical ingredient; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers:
|Trade name of the drug
||Pharmaceutical forms and doses
||Tablets; Oral; Misoprostol 100 mcgTablets; Oral; Misoprostol 200 mcg
||ApotexAgencia Lei Va HongHind Wing
||Tablets; Oral; Misoprostol 25 mcgTablets; Oral; Misoprostol 100 mcgTablets; Oral; Misoprostol 200 mcg
||Tablets; Oral; Misoprostol 100 mcgTablets; Oral; Misoprostol 200 mcg
||PfizerContinental PharmaGD SearleNPIL PharmaceuticalsPerrigoPrimal ChemicalThe Glory MedicinaZuellig Pharma
||Tablets; Oral; Misoprostol 200 mcg
||HRA PharmaLinepharma International
||Tablets; Oral; Misoprostol 200 mcg
Misoprostol main article on Wikipedia: https://en.wikipedia.org/wiki/Misoprostol
Misoprostol compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/Misoprostol
Misoprostol on DrugBank: https://go.drugbank.com/drugs/DB00929
Misoprostol FAQ on MedlinePlus (revised 11/15/2017): https://medlineplus.gov/druginfo/meds/a689009.html
Misoprostol Apotheca tablets drug label info on DailyMed (revised February 1, 2017): https://dailymed.nlm.nih.gov/dailymed/lookup...
Cytotec (Misoprostol) tablets drug label info on DailyMed (revised April 1, 2010): https://dailymed.nlm.nih.gov/dailymed/drugInfo...
Misoprostol containing drugs on Drugs-About.com: https://drugs-about.com/ing/misoprostol.html
Misoprostol for sale on Pharma Doctor: https://pharma-doctor.com/misoprostol.html
Cytotec (Misoprostol) 100 mcg and 200 mcg tablets official prescribing and patient information from the U.S. FDA (revised 07/10/2015): https://www.accessdata.fda.gov/drugsatfda_docs/label...
Cytotec (Misoprostol) 100 mcg and 200 mcg tablets prescribing and patient information from Pfizer pharmaceutical company (revised February 2021): https://labeling.pfizer.com/ShowLabeling.aspx?id=559
Cytotec (Misoprostol) tablets U.S. patient product information from Pfizer (revised March 2002): https://pfe-pfizercom-d8-prod.s3.amazonaws.com/products/ppi_cytotec.pdf
Apo-Misoprostol tablets information for the patient (medication guide) from Apotex pharmaceutical company: https://www.aapharma.ca/downloads/en/PIL/0138_PIL.pdf
GyMiso (Misoprostol) tablets consumer medicine information (CMI) leaflet from NPS MedicineWise (revised 01 May 2018): https://www.nps.org.au/medicine-finder/gy-miso-tablets
Cytotec 200 microgram tablets Misoprostol package information leaflet on Medicines.org.uk (revised 06/2018): https://www.medicines.org.uk/emc/files/pil.1642.pdf
Revised: March 2021
Home | Research | About Us | Reproductive Justice Agenda | Movement Building | Community Organizing | Get Involved
Copyright © 1998 - 2021 Asian Communities for Reproductive Justice (ACRJ). All Rights Reserved.